Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
Chaperone-Mediated Autophagy Upregulation Rescues Megalin Expression and Localization in Cystinotic Proximal Tubule Cells.

Frontiers in endocrinology

Zhang J, He J, Johnson JL, Rahman F, Gavathiotis E, Cuervo AM, Catz SD.
PMID: 30774622
Front Endocrinol (Lausanne). 2019 Feb 01;10:21. doi: 10.3389/fendo.2019.00021. eCollection 2019.

Cystinosis is a lysosomal storage disorder caused by defects in

Cite
Zhang J, He J, Johnson JL, et al. Chaperone-Mediated Autophagy Upregulation Rescues Megalin Expression and Localization in Cystinotic Proximal Tubule Cells. Front Endocrinol (Lausanne). 2019;10:21doi: 10.3389/fendo.2019.00021.
Zhang, J., He, J., Johnson, J. L., Rahman, F., Gavathiotis, E., Cuervo, A. M., & Catz, S. D. (2019). Chaperone-Mediated Autophagy Upregulation Rescues Megalin Expression and Localization in Cystinotic Proximal Tubule Cells. Frontiers in endocrinology, 1021. https://doi.org/10.3389/fendo.2019.00021
Zhang, Jinzhong, et al. "Chaperone-Mediated Autophagy Upregulation Rescues Megalin Expression and Localization in Cystinotic Proximal Tubule Cells." Frontiers in endocrinology vol. 10 (2019): 21. doi: https://doi.org/10.3389/fendo.2019.00021
Zhang J, He J, Johnson JL, Rahman F, Gavathiotis E, Cuervo AM, Catz SD. Chaperone-Mediated Autophagy Upregulation Rescues Megalin Expression and Localization in Cystinotic Proximal Tubule Cells. Front Endocrinol (Lausanne). 2019 Feb 01;10:21. doi: 10.3389/fendo.2019.00021. eCollection 2019. PMID: 30774622; PMCID: PMC6367655.
Copy Download .nbib Format: NLM
Recognition and Stabilization of Quadruplex DNA by a Potent New Telomerase Inhibitor: NMR Studies of the 2:1 Complex of a Pentacyclic Methylacridinium Cation with d(TTAGGGT)(4) We thank the EPSRC of the UK and AstraZeneca for financial support to E.G. M.F.G.S. and R.A.H. are supported by the Cancer Research Campaign of the UK. .

Angewandte Chemie (International ed. in English)

Gavathiotis E, Heald RA, Stevens MF, Searle MS.
PMID: 12404405
Angew Chem Int Ed Engl. 2001 Dec 17;40(24):4749-4751. doi: 10.1002/1521-3773(20011217)40:24<4749::aid-anie4749>3.0.co;2-i.

No abstract available.

Cite
Gavathiotis E, Heald RA, Stevens MF, et al. Recognition and Stabilization of Quadruplex DNA by a Potent New Telomerase Inhibitor: NMR Studies of the 2:1 Complex of a Pentacyclic Methylacridinium Cation with d(TTAGGGT)(4) We thank the EPSRC of the UK and AstraZeneca for financial support to E.G. M.F.G.S. and R.A.H. are supported by the Cancer Research Campaign of the UK. . Angew Chem Int Ed Engl. 2001;40(24):4749-4751doi: 10.1002/1521-3773(20011217)40:24<4749::aid-anie4749>3.0.co;2-i.
Gavathiotis, E., Heald, R. A., Stevens, M. F., & Searle, M. S. (2001). Recognition and Stabilization of Quadruplex DNA by a Potent New Telomerase Inhibitor: NMR Studies of the 2:1 Complex of a Pentacyclic Methylacridinium Cation with d(TTAGGGT)(4) We thank the EPSRC of the UK and AstraZeneca for financial support to E.G. M.F.G.S. and R.A.H. are supported by the Cancer Research Campaign of the UK. . Angewandte Chemie (International ed. in English), 40(24), 4749-4751. https://doi.org/10.1002/1521-3773(20011217)40:24<4749::aid-anie4749>3.0.co;2-i
Gavathiotis, Evripidis, et al. "Recognition and Stabilization of Quadruplex DNA by a Potent New Telomerase Inhibitor: NMR Studies of the 2:1 Complex of a Pentacyclic Methylacridinium Cation with d(TTAGGGT)(4) We thank the EPSRC of the UK and AstraZeneca for financial support to E.G. M.F.G.S. and R.A.H. are supported by the Cancer Research Campaign of the UK. ." Angewandte Chemie (International ed. in English) vol. 40,24 (2001): 4749-4751. doi: https://doi.org/10.1002/1521-3773(20011217)40:24<4749::aid-anie4749>3.0.co;2-i
Gavathiotis E, Heald RA, Stevens MF, Searle MS. Recognition and Stabilization of Quadruplex DNA by a Potent New Telomerase Inhibitor: NMR Studies of the 2:1 Complex of a Pentacyclic Methylacridinium Cation with d(TTAGGGT)(4) We thank the EPSRC of the UK and AstraZeneca for financial support to E.G. M.F.G.S. and R.A.H. are supported by the Cancer Research Campaign of the UK. . Angew Chem Int Ed Engl. 2001 Dec 17;40(24):4749-4751. doi: 10.1002/1521-3773(20011217)40:24<4749::aid-anie4749>3.0.co;2-i. PMID: 12404405.
Copy Download .nbib Format: NLM
ICBS 2017 in Shanghai-Illuminating Life with Chemical Innovation.

ACS chemical biology

Zhang Q, Zhang J, Gavathiotis E.
PMID: 29677443
ACS Chem Biol. 2018 May 18;13(5):1111-1122. doi: 10.1021/acschembio.8b00220. Epub 2018 May 02.

No abstract available.

Cite
Zhang Q, Zhang J, Gavathiotis E. ICBS 2017 in Shanghai-Illuminating Life with Chemical Innovation. ACS Chem Biol. 2018;13(5):1111-1122doi: 10.1021/acschembio.8b00220.
Zhang, Q., Zhang, J., & Gavathiotis, E. (2018). ICBS 2017 in Shanghai-Illuminating Life with Chemical Innovation. ACS chemical biology, 13(5), 1111-1122. https://doi.org/10.1021/acschembio.8b00220
Zhang, Qi, et al. "ICBS 2017 in Shanghai-Illuminating Life with Chemical Innovation." ACS chemical biology vol. 13,5 (2018): 1111-1122. doi: https://doi.org/10.1021/acschembio.8b00220
Zhang Q, Zhang J, Gavathiotis E. ICBS 2017 in Shanghai-Illuminating Life with Chemical Innovation. ACS Chem Biol. 2018 May 18;13(5):1111-1122. doi: 10.1021/acschembio.8b00220. Epub 2018 May 02. PMID: 29677443; PMCID: PMC6855916.
Copy Download .nbib Format: NLM
Pulling the BAX trigger for tumor cell death.

Oncotarget

Reyna DE, Gavathiotis E.
PMID: 29492188
Oncotarget. 2018 Jan 12;9(9):8204-8205. doi: 10.18632/oncotarget.24201. eCollection 2018 Feb 02.

No abstract available.

Cite
Reyna DE, Gavathiotis E. Pulling the BAX trigger for tumor cell death. Oncotarget. 2018;9(9):8204-8205doi: 10.18632/oncotarget.24201.
Reyna, D. E., & Gavathiotis, E. (2018). Pulling the BAX trigger for tumor cell death. Oncotarget, 9(9), 8204-8205. https://doi.org/10.18632/oncotarget.24201
Reyna, Denis E, and Gavathiotis, Evripidis. "Pulling the BAX trigger for tumor cell death." Oncotarget vol. 9,9 (2018): 8204-8205. doi: https://doi.org/10.18632/oncotarget.24201
Reyna DE, Gavathiotis E. Pulling the BAX trigger for tumor cell death. Oncotarget. 2018 Jan 12;9(9):8204-8205. doi: 10.18632/oncotarget.24201. eCollection 2018 Feb 02. PMID: 29492188; PMCID: PMC5823591.
Copy Download .nbib Format: NLM
Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1.

Oncotarget

Ow TJ, Fulcher CD, Thomas C, Broin PÓ, López A, Reyna DE, Smith RV, Sarta C, Prystowsky MB, Schlecht NF, Schiff BA, Rosenblatt G, Belbin TJ, Harris TM, Childs GC, Kawachi N, Guha C, Gavathiotis E.
PMID: 30728900
Oncotarget. 2019 Jan 11;10(4):494-510. doi: 10.18632/oncotarget.26563. eCollection 2019 Jan 11.

Mechanisms of treatment resistance in head and neck squamous cell carcinoma (HNSCC) are not well characterized. In this study, HNSCC tumors from a cohort of prospectively enrolled subjects on an ongoing tissue banking study were divided into those that...

Cite
Ow TJ, Fulcher CD, Thomas C, et al. Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1. Oncotarget. 2019;10(4):494-510doi: 10.18632/oncotarget.26563.
Ow, T. J., Fulcher, C. D., Thomas, C., Broin, P. �. �., López, A., Reyna, D. E., Smith, R. V., Sarta, C., Prystowsky, M. B., Schlecht, N. F., Schiff, B. A., Rosenblatt, G., Belbin, T. J., Harris, T. M., Childs, G. C., Kawachi, N., Guha, C., & Gavathiotis, E. (2019). Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1. Oncotarget, 10(4), 494-510. https://doi.org/10.18632/oncotarget.26563
Ow, Thomas J, et al. "Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1." Oncotarget vol. 10,4 (2019): 494-510. doi: https://doi.org/10.18632/oncotarget.26563
Ow TJ, Fulcher CD, Thomas C, Broin PÓ, López A, Reyna DE, Smith RV, Sarta C, Prystowsky MB, Schlecht NF, Schiff BA, Rosenblatt G, Belbin TJ, Harris TM, Childs GC, Kawachi N, Guha C, Gavathiotis E. Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1. Oncotarget. 2019 Jan 11;10(4):494-510. doi: 10.18632/oncotarget.26563. eCollection 2019 Jan 11. PMID: 30728900; PMCID: PMC6355180.
Copy Download .nbib Format: NLM
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Cancer cell

Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI.
PMID: 27622340
Cancer Cell. 2016 Sep 12;30(3):501-503. doi: 10.1016/j.ccell.2016.08.008. Epub 2016 Sep 12.

No abstract available.

Cite
Karoulia Z, Wu Y, Ahmed TA, et al. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell. 2016;30(3):501-503doi: 10.1016/j.ccell.2016.08.008.
Karoulia, Z., Wu, Y., Ahmed, T. A., Xin, Q., Bollard, J., Krepler, C., Wu, X., Zhang, C., Bollag, G., Herlyn, M., Fagin, J. A., Lujambio, A., Gavathiotis, E., & Poulikakos, P. I. (2016). An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer cell, 30(3), 501-503. https://doi.org/10.1016/j.ccell.2016.08.008
Karoulia, Zoi, et al. "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling." Cancer cell vol. 30,3 (2016): 501-503. doi: https://doi.org/10.1016/j.ccell.2016.08.008
Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell. 2016 Sep 12;30(3):501-503. doi: 10.1016/j.ccell.2016.08.008. Epub 2016 Sep 12. PMID: 27622340.
Copy Download .nbib Format: NLM
Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome.

Cell

Bourdenx M, Martín-Segura A, Scrivo A, Rodriguez-Navarro JA, Kaushik S, Tasset I, Diaz A, Storm NJ, Xin Q, Juste YR, Stevenson E, Luengo E, Clement CC, Choi SJ, Krogan NJ, Mosharov EV, Santambrogio L, Grueninger F, Collin L, Swaney DL, Sulzer D, Gavathiotis E, Cuervo AM.
PMID: 33891876
Cell. 2021 May 13;184(10):2696-2714.e25. doi: 10.1016/j.cell.2021.03.048. Epub 2021 Apr 22.

Components of the proteostasis network malfunction in aging, and reduced protein quality control in neurons has been proposed to promote neurodegeneration. Here, we investigate the role of chaperone-mediated autophagy (CMA), a selective autophagy shown to degrade neurodegeneration-related proteins, in...

Cite
Bourdenx M, Martín-Segura A, Scrivo A, et al. Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell. 2021;184(10):2696-2714.e25doi: 10.1016/j.cell.2021.03.048.
Bourdenx, M., Martín-Segura, A., Scrivo, A., Rodriguez-Navarro, J. A., Kaushik, S., Tasset, I., Diaz, A., Storm, N. J., Xin, Q., Juste, Y. R., Stevenson, E., Luengo, E., Clement, C. C., Choi, S. J., Krogan, N. J., Mosharov, E. V., Santambrogio, L., Grueninger, F., Collin, L., Swaney, D. L., Sulzer, D., Gavathiotis, E., & Cuervo, A. M. (2021). Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell, 184(10), 2696-2714.e25. https://doi.org/10.1016/j.cell.2021.03.048
Bourdenx, Mathieu, et al. "Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome." Cell vol. 184,10 (2021): 2696-2714.e25. doi: https://doi.org/10.1016/j.cell.2021.03.048
Bourdenx M, Martín-Segura A, Scrivo A, Rodriguez-Navarro JA, Kaushik S, Tasset I, Diaz A, Storm NJ, Xin Q, Juste YR, Stevenson E, Luengo E, Clement CC, Choi SJ, Krogan NJ, Mosharov EV, Santambrogio L, Grueninger F, Collin L, Swaney DL, Sulzer D, Gavathiotis E, Cuervo AM. Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. Cell. 2021 May 13;184(10):2696-2714.e25. doi: 10.1016/j.cell.2021.03.048. Epub 2021 Apr 22. PMID: 33891876; PMCID: PMC8152331.
Copy Download .nbib Format: NLM
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.

Blood cancer journal

Rahmani NE, Ramachandra N, Sahu S, Gitego N, Lopez A, Pradhan K, Bhagat TD, Gordon-Mitchell S, Pena BR, Kazemi M, Rao K, Giricz O, Maqbool SB, Olea R, Zhao Y, Zhang J, Dolatshad H, Tittrea V, Tatwavedi D, Singh S, Lee J, Sun T, Steidl U, Shastri A, Inoue D, Abdel-Wahab O, Pellagatti A, Gavathiotis E, Boultwood J, Verma A.
PMID: 34548471
Blood Cancer J. 2021 Sep 21;11(9):157. doi: 10.1038/s41408-021-00541-0.

The BCL2-inhibitor, Venetoclax (VEN), has shown significant anti-leukemic efficacy in combination with the DNMT-inhibitor, Azacytidine (AZA). To explore the mechanisms underlying the selective sensitivity of mutant leukemia cells to VEN and AZA, we used cell-based isogenic models containing a...

Cite
Rahmani NE, Ramachandra N, Sahu S, et al. ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer J. 2021;11(9):157doi: 10.1038/s41408-021-00541-0.
Rahmani, N. E., Ramachandra, N., Sahu, S., Gitego, N., Lopez, A., Pradhan, K., Bhagat, T. D., Gordon-Mitchell, S., Pena, B. R., Kazemi, M., Rao, K., Giricz, O., Maqbool, S. B., Olea, R., Zhao, Y., Zhang, J., Dolatshad, H., Tittrea, V., Tatwavedi, D., Singh, S., Lee, J., Sun, T., Steidl, U., Shastri, A., Inoue, D., Abdel-Wahab, O., Pellagatti, A., Gavathiotis, E., Boultwood, J., & Verma, A. (2021). ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood cancer journal, 11(9), 157. https://doi.org/10.1038/s41408-021-00541-0
Rahmani, Nora E, et al. "ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine." Blood cancer journal vol. 11,9 (2021): 157. doi: https://doi.org/10.1038/s41408-021-00541-0
Rahmani NE, Ramachandra N, Sahu S, Gitego N, Lopez A, Pradhan K, Bhagat TD, Gordon-Mitchell S, Pena BR, Kazemi M, Rao K, Giricz O, Maqbool SB, Olea R, Zhao Y, Zhang J, Dolatshad H, Tittrea V, Tatwavedi D, Singh S, Lee J, Sun T, Steidl U, Shastri A, Inoue D, Abdel-Wahab O, Pellagatti A, Gavathiotis E, Boultwood J, Verma A. ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer J. 2021 Sep 21;11(9):157. doi: 10.1038/s41408-021-00541-0. PMID: 34548471; PMCID: PMC8455571.
Copy Download .nbib Format: NLM
An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway.

Molecular cell

Garner TP, Reyna DE, Priyadarshi A, Chen HC, Li S, Wu Y, Ganesan YT, Malashkevich VN, Cheng EH, Gavathiotis E.
PMID: 27768876
Mol Cell. 2016 Oct 20;64(2):431. doi: 10.1016/j.molcel.2016.10.005.

No abstract available.

Cite
Garner TP, Reyna DE, Priyadarshi A, et al. An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway. Mol Cell. 2016;64(2):431doi: 10.1016/j.molcel.2016.10.005.
Garner, T. P., Reyna, D. E., Priyadarshi, A., Chen, H. C., Li, S., Wu, Y., Ganesan, Y. T., Malashkevich, V. N., Cheng, E. H., & Gavathiotis, E. (2016). An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway. Molecular cell, 64(2), 431. https://doi.org/10.1016/j.molcel.2016.10.005
Garner, Thomas P, et al. "An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway." Molecular cell vol. 64,2 (2016): 431. doi: https://doi.org/10.1016/j.molcel.2016.10.005
Garner TP, Reyna DE, Priyadarshi A, Chen HC, Li S, Wu Y, Ganesan YT, Malashkevich VN, Cheng EH, Gavathiotis E. An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway. Mol Cell. 2016 Oct 20;64(2):431. doi: 10.1016/j.molcel.2016.10.005. PMID: 27768876.
Copy Download .nbib Format: NLM
Chaperone-mediated autophagy: a gatekeeper of neuronal proteostasis.

Autophagy

Bourdenx M, Gavathiotis E, Cuervo AM.
PMID: 34110247
Autophagy. 2021 Aug;17(8):2040-2042. doi: 10.1080/15548627.2021.1935007. Epub 2021 Jun 10.

Different types of autophagy co-exist in all mammalian cells, however, the specific contribution of each of these autophagic pathways to the maintenance of cellular proteostasis and cellular function remains unknown. In this work, we have investigated the consequences of...

Cite
Bourdenx M, Gavathiotis E, Cuervo AM. Chaperone-mediated autophagy: a gatekeeper of neuronal proteostasis. Autophagy. 2021;17(8):2040-2042doi: 10.1080/15548627.2021.1935007.
Bourdenx, M., Gavathiotis, E., & Cuervo, A. M. (2021). Chaperone-mediated autophagy: a gatekeeper of neuronal proteostasis. Autophagy, 17(8), 2040-2042. https://doi.org/10.1080/15548627.2021.1935007
Bourdenx, Mathieu, et al. "Chaperone-mediated autophagy: a gatekeeper of neuronal proteostasis." Autophagy vol. 17,8 (2021): 2040-2042. doi: https://doi.org/10.1080/15548627.2021.1935007
Bourdenx M, Gavathiotis E, Cuervo AM. Chaperone-mediated autophagy: a gatekeeper of neuronal proteostasis. Autophagy. 2021 Aug;17(8):2040-2042. doi: 10.1080/15548627.2021.1935007. Epub 2021 Jun 10. PMID: 34110247; PMCID: PMC8386735.
Copy Download .nbib Format: NLM
Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax.

Molecular cancer research : MCR

Gadsden NJ, Fulcher CD, Li D, Shrivastava N, Thomas C, Segall JE, Prystowsky MB, Schlecht NF, Gavathiotis E, Ow TJ.
PMID: 33495400
Mol Cancer Res. 2021 May;19(5):862-873. doi: 10.1158/1541-7786.MCR-20-0915. Epub 2021 Jan 25.

We demonstrate that inhibition of cyclin-dependent kinases 4/6 (CDK4/6) leads to senescence in human papillomavirus (HPV)-negative (-) head and neck squamous cell carcinoma (HNSCC), but not in HPV-positive (+) HNSCC. The BCL-2 family inhibitor, navitoclax, has been shown to...

Cite
Gadsden NJ, Fulcher CD, Li D, et al. Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax. Mol Cancer Res. 2021;19(5):862-873doi: 10.1158/1541-7786.MCR-20-0915.
Gadsden, N. J., Fulcher, C. D., Li, D., Shrivastava, N., Thomas, C., Segall, J. E., Prystowsky, M. B., Schlecht, N. F., Gavathiotis, E., & Ow, T. J. (2021). Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax. Molecular cancer research : MCR, 19(5), 862-873. https://doi.org/10.1158/1541-7786.MCR-20-0915
Gadsden, Nicholas J, et al. "Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax." Molecular cancer research : MCR vol. 19,5 (2021): 862-873. doi: https://doi.org/10.1158/1541-7786.MCR-20-0915
Gadsden NJ, Fulcher CD, Li D, Shrivastava N, Thomas C, Segall JE, Prystowsky MB, Schlecht NF, Gavathiotis E, Ow TJ. Palbociclib Renders Human Papilloma Virus-Negative Head and Neck Squamous Cell Carcinoma Vulnerable to the Senolytic Agent Navitoclax. Mol Cancer Res. 2021 May;19(5):862-873. doi: 10.1158/1541-7786.MCR-20-0915. Epub 2021 Jan 25. PMID: 33495400; PMCID: PMC8314015.
Copy Download .nbib Format: NLM
Physiological and pharmacological modulation of BAX.

Trends in pharmacological sciences

Spitz AZ, Gavathiotis E.
PMID: 34848097
Trends Pharmacol Sci. 2021 Nov 27; doi: 10.1016/j.tips.2021.11.001. Epub 2021 Nov 27.

Bcl-2-associated X protein (BAX) is a critical executioner of mitochondrial regulated cell death through its lethal activity of permeabilizing the mitochondrial outer membrane (MOM). While the physiological function of BAX ensures tissue homeostasis, dysregulation of BAX leads to aberrant...

Cite
Spitz AZ, Gavathiotis E. Physiological and pharmacological modulation of BAX. Trends Pharmacol Sci. 2021;doi: 10.1016/j.tips.2021.11.001.
Spitz, A. Z., & Gavathiotis, E. (2021). Physiological and pharmacological modulation of BAX. Trends in pharmacological sciences, . https://doi.org/10.1016/j.tips.2021.11.001
Spitz, Adam Z, and Gavathiotis, Evripidis. "Physiological and pharmacological modulation of BAX." Trends in pharmacological sciences vol. (2021). doi: https://doi.org/10.1016/j.tips.2021.11.001
Spitz AZ, Gavathiotis E. Physiological and pharmacological modulation of BAX. Trends Pharmacol Sci. 2021 Nov 27; doi: 10.1016/j.tips.2021.11.001. Epub 2021 Nov 27. PMID: 34848097.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries